Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity
- 3 October 2006
- journal article
- basic science
- Published by Wolters Kluwer Health in AIDS
- Vol. 20 (15) , 1923-1930
- https://doi.org/10.1097/01.aids.0000247113.43714.5e
Abstract
Objective: Previous studies have shown that broadly neutralizing antibodies (NAb) are more frequent in long-term non-progressors (LTNP) than in other HIV-1 infected patients, but nothing is known about the envelope regions targeted by these broadly NAb. We investigated whether the breadth of neutralizing activity of sera was associated with the presence of specific antibodies (2F5- and/or 4E10-like, b12-like or 2G12-like antibodies) directed against conserved epitopes known to be involved in broad neutralization. Methods: We assessed the ability of sera from 67 LTNP of the French ANRS cohort (ANRS CO15) to neutralize four heterologous primary isolates of four various clades. Competitive and non-competitive ELISA were developed for the specific comparison of levels of antibodies against these specific epitopes in neutralizing and non-neutralizing sera from LTNP. Results: We found that higher 2G12-like antibody levels were significantly associated with the broadest neutralizing activity in sera from LTNP. Levels of 2G12-like antibodies were higher in the sera that neutralized the four isolates than in the others, with a median of 5.7 μg/ml [interquartile range (IQR), 2.7–9.3 μg/ml] versus 2.3 μg/ml (IQR, 1.1–3.9 μg/ml) (Mann–Whitney test, P = 0.03). Levels of antibodies against the other targeted envelope epitopes did not differ significantly between broadly and non-broadly neutralizing sera. Conclusion: These results suggest that the antigenicity of the ‘silent face’ of gp120 that exposes the 2G12 epitope should be analysed in more detail, to find ways to induce broadly neutralizing antibodies.Keywords
This publication has 55 references indexed in Scilit:
- Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal AntibodiesJournal of Virology, 2004
- Evolutionary Dynamics of the Glycan Shield of theHuman Immunodeficiency Virus Envelope during Natural Infection andImplications for Exposure of the 2G12EpitopeJournal of Virology, 2004
- Interclade Neutralization and Enhancement of Human Immunodeficiency Virus Type 1 Identified by an Assay Using HeLa Cells Expressing Both CD4 Receptor and CXCR4/CCR5 CoreceptorsThe Journal of Infectious Diseases, 2004
- A Potent Cross-Clade Neutralizing Human Monoclonal Antibody against a Novel Epitope on gp41 of Human Immunodeficiency Virus Type 1AIDS Research and Human Retroviruses, 2001
- HIV Type 1-Specific IgG2 Antibodies: Markers of Helper T Cell Type 1 Response and Prognostic Marker of Long-Term NonprogressionAIDS Research and Human Retroviruses, 2001
- Assessment of Antibody Assays for Identifying and Distinguishing Recent from Long-Term HIV Type 1 InfectionAIDS Research and Human Retroviruses, 2001
- Enhancing antibodies in HIV infectionParasitology, 1997
- Human Immunodeficiency Virus Type 1 Neutralizing Antibody Serotyping Using Serum Pools and an Infectivity Reduction AssayAIDS Research and Human Retroviruses, 1996
- Diversity of Antibody Binding to V3 Peptides Representing Consensus Sequences of HIV Type 1 Genotypes A to E: An Approach for HIV Type 1 Serological SubtypingAIDS Research and Human Retroviruses, 1996
- Antibody-enhanced dengue virus infection in primate leukocytesNature, 1977